Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials

Overview of attention for article published in BMC Cancer, March 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 22 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,832 followers.

RT @Senology: #BestStudyoftheDay: Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard che…

30 Mar 2022

Reply Repost Favourite

#BestStudyoftheDay: Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? https://t.co/9xflY618i9 - BMC Cancer - #senology #breast #cancer #oncology

28 Mar 2022

Reply Repost Favourite

New article: Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials https://t.co/pH9QMcJtpr #breastcancer #oncology https://t.co/369Zc9lS

14 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.